Lilly is an API and finished-dose manufacturer based in Spain. It appears in 280 regulatory filings across 7 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA, AEMPS (ES) and MINSA (CR). Its GMP standing is certified by MFDS (Korea), ANVISA (Brazil) and US FDA, among 6 authorities. Its most recent recorded inspection, by US FDA, closed on 14 February 2024 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Alcobendas, United Arab Emirates | Not on file |
| MADRID, Spain | Not on file |
| Madrid, Spain | Not on file |
| Madrid, Spain | Not on file |
| Spain, Spain | 3000235541 |
| Molecule | Regulators | Docs |
|---|---|---|
| Olanzapine | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | 191 | 1 |
| AEMPS (ES) | 71 | 1 |
| MINSA (CR) | 6 | None |
| SFDA (Saudi Arabia) | 5 | None |
| NAFDAC (NG) | 3 | 1 |
| ANPP (DZ) | 3 | None |
| MFDS (Korea) | None | 2 |
| ANVISA (Brazil) | None | 1 |
| EMA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2025 | $65.2B | Not reported | Not reported |
| 2024 | $45.0B | Not reported | Not reported |
| 2023 | $34.1B | Not reported | Not reported |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Lilly comes back tiered against every other supplier able to file there.
Start for free